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Reply to Farmakiotis et al
TO THE EDITOR—Our recent development
of a human Salmonella Typhi challenge
model provided a detailed description of
the clinical proﬁle and associated patho-
logical changes seen during typhoid
fever [1]. Alterations in hematological pa-
rameters included decreases in hemoglo-
bin and hematocrit in all participants,
and, in those diagnosed with typhoid, de-
creases in both platelet and total white
cell counts (WCCs). The reduction in
WCC manifested as falls in neutrophil
and eosinophil count, with the eosinophil
count declining from 6 days prior to diag-
nosis. This was the earliest of all the blood
parameters to change and was seen in all
but 1 participant.
Eosinopenia in our study was part of a
general suppression of hematopoiesis,
possibly consequent to inﬁltration of the
bone marrow by Salmonella Typhi. As
Farmakiotis et al note, the ﬁnding of eo-
sinopenia has previously been reported in
typhoid, although not universally. For ex-
ample, in 2 series of 28 and 54 children
with typhoid, eosinopenia occurred in
71.4% and 86.6%, respectively [2, 3]. Sim-
ilarly, 10 of 17 returning travelers with ty-
phoid fever were eosinopenic [2]. These
data call into question the diagnostic
value of the eosinophil count in isolation,
and highlight the need to assess the clin-
ical picture in its entirety. Clinical diag-
nosis of typhoid fever is challenging,
particularly in endemic settings where
the presentation can be indistinguishable
from other common febrile diseases in-
cluding malaria and dengue fever [4].
The data presented by Farmakiotis et al
in their correspondence pertain to nonty-
phoidal Salmonella gastroenteritis, which
is pathologically distinct from typhoid
fever. Typhoid fever is a severe systemic
infection caused by the human-restricted
pathogen S. Typhi, affecting an estimated
26.9 million people annually, of whom
1% die [5]. In contrast, Salmonella gastro-
enteritis results from a large number of
nonhuman restricted Salmonella serovars
and is self-limiting in nonimmunosup-
pressed hosts. Eosinopenia is recognized
in a variety of infectious diseases and in
sepsis syndrome [6, 7]; however the un-
derlying mechanism in infection, and
more speciﬁcally in typhoid infection, is
unclear. In health, eosinophils principally
reside at mucosal surfaces including the
gut mucosa [8], and it is possible that in-
creased marginalization of these cells
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during infection at this site may account
for the early and marked decrease [9].
These uncertainties highlight the signiﬁ-
cant gaps remaining in our understand-
ing of both typhoid and other enteric
infections as well as more global mecha-
nisms of the mucosal immune response.
Both need to be addressed to meaningful-
ly impact the clinical management of pa-
tients and vaccination strategies. Human
challenge studies provide an ideal setting
to enable the detailed investigation of dis-
ease and immunobiology, particularly for
human-restricted pathogens such as Sal-
monella Typhi [10].
Both our report and those of Farma-
kiotis and colleagues further highlight
the lack of accurate diagnostic tests for
typhoid and other Salmonella serovars,
especially in endemic regions where
resources are frequently limited. Prompt
diagnosis and treatment of typhoid de-
creases complications and limits the op-
portunity for onward transmission [4].
New, reliable diagnostic tests are needed
to prevent treatment delays, minimize
morbidity and mortality, prevent inap-
propriate use of antimicrobials, and pro-
vide reliable epidemiological data.
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